Imperial College London
Alternate

ProfessorWaljitDhillo

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Professor of Endocrinology & Metabolism
 
 
 
//

Contact

 

+44 (0)20 7594 3487w.dhillo Website

 
 
//

Assistant

 

Ms Suzanne Wheeler +44 (0)20 7594 3487

 
//

Location

 

6N6ECommonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Comninos:2022:clinem/dgac117,
author = {Comninos, AN and Hansen, MS and Courtney, A and Choudhury, S and Yang, L and Mills, EG and Phylactou, M and Busbridge, M and Khir, M and Thaventhiran, T and Bech, P and Tan, T and Abbara, A and Frost, M and Dhillo, WS},
doi = {clinem/dgac117},
journal = {Journal of Clinical Endocrinology and Metabolism},
title = {Acute effects of kisspeptin administration on bone metabolism in healthy men},
url = {http://dx.doi.org/10.1210/clinem/dgac117},
volume = {107},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - CONTEXT: Osteoporosis results from disturbances in bone formation and resorption. Recent non-human data suggests that the reproductive hormone, kisspeptin, directly stimulates osteoblast differentiation in vitro and thus could have clinical therapeutic potential. However, the effects of kisspeptin on human bone metabolism are currently unknown. OBJECTIVE: To assess the effects of kisspeptin on human bone metabolism in vitro and in vivo. DESIGN: In vitro study: Mono- and co-cultures of human osteoblasts and osteoclasts treated with kisspeptin. Clinical study: Randomized, placebo-controlled, double-blind, two-way crossover clinical study in twenty-six men investigating the effects of acute kisspeptin administration (90 minutes) on human bone metabolism, with blood sampling every 30 minutes to +90 minutes. PARTICIPANTS: In vitro study: Twelve male blood donors and eight patients undergoing hip replacement surgery. Clinical Study: Twenty-six healthy eugonadal men (age 26.8±5.8 years). INTERVENTION: Kisspeptin (versus placebo). MAIN OUTCOME MEASURES: Changes in bone parameters and turnover markers. RESULTS: Incubation with kisspeptin in vitro increased alkaline phosphatase levels in human bone marrow mesenchymal stem cells by 41.1% (P=0.0022), and robustly inhibited osteoclastic resorptive activity by up to 53.4% (P<0.0001), in a dose-dependent manner. Kisspeptin administration to healthy men increased osteoblast activity, as evidenced by a 20.3% maximal increase in total osteocalcin (P=0.021) and 24.3% maximal increase in carboxylated osteocalcin levels (P=0.014). CONCLUSIONS: Collectively, these data provide the first human evidence that kisspeptin promotes osteogenic differentiation of osteoblast progenitors and inhibits bone resorption in vitro. Furthermore, kisspeptin acutely increases the bone formation marker osteocalcin but not resorption markers in healthy men, independent of downstream sex-steroid levels. Kisspeptin could therefore have clinical thera
AU  - Comninos,AN
AU  - Hansen,MS
AU  - Courtney,A
AU  - Choudhury,S
AU  - Yang,L
AU  - Mills,EG
AU  - Phylactou,M
AU  - Busbridge,M
AU  - Khir,M
AU  - Thaventhiran,T
AU  - Bech,P
AU  - Tan,T
AU  - Abbara,A
AU  - Frost,M
AU  - Dhillo,WS
DO  - clinem/dgac117
PY  - 2022///
SN  - 0021-972X
TI  - Acute effects of kisspeptin administration on bone metabolism in healthy men
T2  - Journal of Clinical Endocrinology and Metabolism
UR  - http://dx.doi.org/10.1210/clinem/dgac117
UR  - https://www.ncbi.nlm.nih.gov/pubmed/35244717
UR  - https://academic.oup.com/jcem/article/107/6/1529/6542434
UR  - http://hdl.handle.net/10044/1/96502
VL  - 107
ER  -
Download